SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Targeting T cells to treat atherosclerosis: Odyssey from bench to bedside

Bullenkamp, J; Dinkla, S; Kaski, JC; Dumitriu, IE (2016) Targeting T cells to treat atherosclerosis: Odyssey from bench to bedside. European Heart Journal - Cardiovascular Pharmacotherapy, 2 (3). pp. 194-199. ISSN 2055-6837 https://doi.org/10.1093/ehjcvp/pvw001
SGUL Authors: Dumitriu, Ingrid Elena

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (268kB) | Preview

Abstract

More than 150 years from the initial description of inflammation in atherosclerotic plaques, randomized clinical trials to test anti-inflammatory therapies in atherosclerosis have recently been initiated. Lymphocytes and macrophages are main participants in the inflammatory response in atherosclerosis. T lymphocytes operate mainly by exerting strong influences on the function of many cells in the immune system and beyond, and co-ordinating their interactions. Importantly, T lymphocytes are not a homogenous population, but include several subsets with specialized functions that can either promote or suppress inflammation. The interactions between these T-lymphocyte subsets have critical consequences on the course and outcome of inflammation. The complexity of the inflammatory response in atherosclerosis poses significant challenges on translating experimental findings into clinical therapies and makes the journey from bench to bedside an arduous one. Here, we summarize recent advances on the role of CD4 + T cells in the inflammatory process in atherosclerosis and discuss potential therapies to modulate these lymphocytes that may provide future breakthroughs in the treatment of atherosclerosis.

Item Type: Article
Additional Information: © The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) > Cardiac (INCCCA)
Journal or Publication Title: European Heart Journal - Cardiovascular Pharmacotherapy
ISSN: 2055-6837
Dates:
DateEvent
July 2016Published
24 January 2016Published Online
13 January 2016Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
PG/10/50/28434British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
PG/13/24/30115British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
PG/14/18/30724British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
URI: https://openaccess.sgul.ac.uk/id/eprint/107719
Publisher's version: https://doi.org/10.1093/ehjcvp/pvw001

Actions (login required)

Edit Item Edit Item